But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. So, the natural ...

We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against the pump and dump ...

NEW HAVEN, Conn., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...

NEW HAVEN, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...

Fintel reports that on January 6, 2026, Citigroup upgraded their outlook for Arvinas (NasdaqGS:ARVN) from Neutral to Buy.

Arvinas, Inc. (NASDAQ:ARVN) unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ARV-102. Results from the randomized, double-blind, placebo-controlled single ...

Tumors positive for estrogen receptors are the most common subtype of breast cancer. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free ...

Arvinas Inc. has appointed Dr. Noah Berkowitz as chief medical officer and added him to its executive committee, the New Haven-based biotech company said this week. He succeeds Dr. Ron Peck, who had ...

Date & Time: Oct. 8, 12:00–1:00 p.m. HST Presentation order: 11 Poster Number: Late Breaker Abstract 22 Additional information including abstracts can be found on the MDS 2025 website. About ARV-102 ...